MedPath
Found 3 clinical trials|View Analysis
Sort by:

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Phase 3
Not yet recruiting
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Drug: BMS-986365
Drug: Enzalutamide
Drug: Docetaxel
Drug: Abiraterone
Drug: Predinsone/Prednisolone
First Posted Date
2025-01-08
Last Posted Date
2025-01-08
Lead Sponsor
Celgene
Target Recruit Count
960
Registration Number
NCT06764485
Locations
🇺🇸

Local Institution - 0330, Birmingham, Alabama, United States

🇺🇸

Local Institution - 0329, Gilbert, Arizona, United States

🇺🇸

Local Institution - 0015, La Jolla, California, United States

and more 227 locations

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

Phase 1
Recruiting
Conditions
Healthy Volunteers
Interventions
Drug: [14C] BMS-986409 + BMS-986410
Drug: [14C] BMS-986410 + BMS-986409
Drug: BMS-986365
Drug: [14C] BMS-986365
First Posted Date
2024-05-29
Last Posted Date
2024-12-12
Lead Sponsor
Celgene
Target Recruit Count
24
Registration Number
NCT06433505
Locations
🇺🇸

Covance Clinical Research Unit - Madison, Madison, Wisconsin, United States

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

Phase 1
Recruiting
Conditions
Healthy Participants
Interventions
Drug: BMS-986365
Drug: Rabeprazole
First Posted Date
2024-05-16
Last Posted Date
2025-01-09
Lead Sponsor
Celgene
Target Recruit Count
82
Registration Number
NCT06417229
Locations
🇺🇸

ICON Lenexa, Lenexa, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath